Viruxan® Forte
1000 mg tablets for oral dosage
Viruxan® Forte based on Inosine Acedoben Dimepranol (IAD) is an antiviral and immunmodulatory OTC medicine that stimulates the immune system’s antiviral defence.1-5
- Shortens the common cold and flu-like diseases, and helps speed up recovery
- Fights the real cause of the common cold, not just the symptoms
- Effectively restores the immune system
- Clinically proven
- Comes in a convenient tablet form in a pack of 12
- Can be taken at any time, irrespective of food intake
DOSAGE
Adults, including the elderly (over 65 years) and children from 1 year:
- Recommended daily dose: 50 mg / kg body weight / day.
- Usual intake: 1 tablet containing 1 g, 3 – 4 times a day.
- Maximum dose: 4 g per day.
TREATMENT ADVICE
- It is recommended to start with treatment as soon as person feels first symptoms.
- Viruxan® Forte should not be taken for longer than 7 days without consulting a physician.
- You can take this medicine with or without food, in equally divided doses throughout the day.
EFFECTIVE EASY-TO-USE SOLUTION
- Viruxan® Forte is intended for oral intake only.
- This medicine should be taken exactly as described in the packaging leaflet or as your pharmacist has advised.
- Check with your doctor or pharmacist if you are unsure.
Open the sachet directly before use.
The sachet’s contents should be dissolved in a glass of cold or room temperature water (at least 100 ml).
Stir the water to dissolve.
SAFETY INSTRUCTIONS
- If you do not feel better or feel worse after 7 days, please consult your doctor immediately.
- Please return unused medicine to a pharmacy.
Keep out of sight and reach of children.
No special storage conditions are required.
Over-the-counter medical product not subject to medical prescription.
Viruxan® Forte, tablet for oral dosage, 1 tablet contains 1000 mg of inosine acedoben dimepranol. Indications: The treatment of patients with viral respiratory infections. Contraindications: Do not use the medicinal product for patients hypersensitive to the active substance or any of the excipients, or patients currently suffering from gout or increased uric acid levels in the blood. Marketing Authorization Holder: Ewopharma International, Prokopa Velkého 52, 811 04 Bratislava, Slovak Republic. OTC Medicine. Please read the package leaflet carefully before use. Further information is available on request from the license holder or SPC.
References:
1. Sliva J, Pantzartzi CN, Votava M. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Adv Ther. 2019 Aug;36(8):1878-1905. doi: 10.1007/s12325-019-00995-6. Epub 2019 Jun 5. PMID: 31168764; PMCID: PMC6822865; 2. CCDS Viruxan 2020; 3. Rumel Ahmed S, Newman AS, O’Daly J, Duffy S, Grafton G, Brady CA, John Curnow S, Barnes NM, Gordon J. Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications. Int Immunopharmacol. 2017 Jan;42:108-114.doi: 10.1016/j.intimp.2016.11.023. Epub 2016 Nov 29. PMID: 27912146; 4. Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study. BMC Infect Dis. 2016 Nov 7;16(1):648. doi: 10.1186/s12879-016-1965-5. PMID: 27821093; PMCID: PMC5100179; 5. Bulgakova VA, Balabolkin II, Katosova LK, Sedova MS, Zubkova IV. Assessment of the efficacy of combined effect immunomodulator inosine pranobex in preventing respiratory infections in children with allergies. Pediatric pharmacology. 2010; 7(5): 30-37